REGISTER: Hear how PetroTal (PTAL) is increasing oil & gas production in Peru. Find out more at the focusIR Feb Investor Webinar. Sign up here.

Less Ads, More Data, More Tools Register for FREE
Sponsored Content
Don't want ads? Click here
Sponsored Content
Don't want ads? Click here

MaxCyte raises 2024 revenue guide again, ahead of final report

Mon, 13th Jan 2025 10:43

(Alliance News) - MaxCyte Inc on Monday raised its 2024 revenue guidance above initial expectations, and above the updated guide reported in December.

The Rockville, Maryland-based provider of cell engineering platform technologies expects fourth-quarter core revenue between USD8.3 million and USD8.5 million, up from USD7.2 million the year prior.

Full-year core revenue is expected between USD32.2 million and USD32.4 million, compared to USD29.8 million in 2023. This represents a growth rate between 8% and 9%.

The firm increased growth expectations as recently as December, when it raised the guide rate to between 6% and 8%. Previous anticipation was for growth to be between flat and 5%.

Total cash, cash equivalents and investments as of December 31 are expected around USD190 million. This builds on initial guidance for 2024 of USD175 million, and December's updated guide of USD185 million.

Still, the cash expectation for 2024 reflects a decrease from USD211 million reported the previous year.

"The operating environment in the cell therapy industry is improving as we move into 2025," commented Maher Masoud, the company's president and chief executive officer.

Masoud added that streamlining efforts had helped return the company to revenue growth.

"We remain confident in the opportunity that exists for MaxCyte in the years ahead," the CEO added.

The firm expects to publish fourth-quarter and annual results in March.

MaxCyte shares rose 1.7% to 357.00 pence each on Monday morning in London.

By Holly Munks, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

Related Shares

More News
12 Feb 2025 10:21

MaxCyte signs SPL deal with TG Therapeutics

(Sharecast News) - MaxCyte announced the signing of a strategic platform licence agreement with TG Therapeutics on Wednesday, granting the biopharmace...

12 Feb 2025 09:30

MaxCyte partners with TG Therapeutics on autoimmune cell therapy

(Alliance News) - MaxCyte Inc on Wednesday said it has signed a strategic platform licence with TG Therapeutics Inc to develop its autoimmune cell the...

30 Jan 2025 16:43

MaxCyte announces acquisition of SeQure Dx

(Sharecast News) - MaxCyte announced on Thursday that it has acquired SeQure Dx, a specialist in on-target and off-target editing assessment services ...

30 Jan 2025 13:55

MaxCyte buys gene therapy analytics firm SeQure Dx

(Alliance News) - MaxCyte Inc on Thursday said it has acquired SeQure Dx Inc, as it looks to improve its gene therapy testing process.

13 Jan 2025 14:34

MaxCyte flags full-year revenue at top end of expectations

(Sharecast News) - Cell-engineering platform technology company MaxCyte said in an update on Friday that it expected core revenue for the fourth quart...

Free Investment Tools

Register for FREE

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.